Clinical Trial Update: Long Term Safety Observation of Crizotinib in Chinese NSCLC Population [Phase 4]

View source ↗

Summary

A Phase 4 long-term safety observation of crizotinib in Chinese patients with ALK- or ROS1-positive non-small cell lung cancer has been terminated with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Xalkori (crizotinib)

Snippet

Sponsor: Pfizer | Conditions: ALK or ROS1-positive NSCLC | Phase 4 | Status: TERMINATED | Results posted: 2024-11-08